MRK250117C87500
- 12.60
- 0.000.00%
Merck & Co Newsroom
Express News | Merck: Allegations in U.S. Lawsuits Involving Gardasil and Gardasil 9 "Have No Merit"
Express News | Merck & Co Inc: "Reaffirmed Its Commitment to Defending the Safety and Efficacy of Its Hpv Vaccines"
Express News | Merck Issues Statement on Gardasil® Litigation
Forecasting The Future: 12 Analyst Projections For Merck & Co
Citi Maintains Merck & Co(MRK.US) With Buy Rating, Cuts Target Price to $125
Merck & Co Analyst Ratings
Express News | Merck & Co Inc : Citigroup Cuts Target Price to $125 From $130
Wells Fargo Maintains Merck & Co(MRK.US) With Hold Rating, Maintains Target Price $110
Wells Fargo Sticks to Their Hold Rating for Merck & Company (MRK)
Merck Insiders Sell US$6.4m Of Stock, Possibly Signalling Caution
Merck Shares Are Trading Higher After the Company Announced WELIREG Has Gained FDA Priority Review.
TD Cowen Adjusts Price Target on Merck to $121 From $140
Merck's WELIREG Gains FDA Priority Review for Treating Advanced Pheochromocytoma and Paraganglioma
Express News | Merck & Co Inc - FDA Sets Pdufa Date of May 26, 2025 for Welireg
Express News | FDA Grants Priority Review to Merck’s Application for Welireg® (Belzutifan) for the Treatment of Patients With Advanced Pheochromocytoma and Paraganglioma (Ppgl)
Optimistic Buy Rating for Merck & Co. Driven by Winrevair Projections and Financial Strength
Is Merck & Co., Inc. (MRK) the Best Dow Stocks to Buy Right Now?
Unusual Options Activity: VFC, PDD and Others Attract Market Bets, VFC V/OI Ratio Reaches 315.8
EST Jan 24th Afternoon Delivery - In the last two hours of trading, 10 options with a high V/OI ratio were detected. With the market volatile, it's crucial to stay informed on the latest options
Merck, Eisai Gastroesophageal Cancer Combo Therapy Meets One Primary Endpoint in Trial
Why Is Billionaire Prem Watsa Bullish on Merck & Co., Inc. (MRK) Now?